Edition:
India

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

3.20USD
9:58pm IST
Change (% chg)

$0.04 (+1.27%)
Prev Close
$3.16
Open
$3.23
Day's High
$3.27
Day's Low
$3.16
Volume
58,656
Avg. Vol
71,165
52-wk High
$3.40
52-wk Low
$1.11

Latest Key Developments (Source: Significant Developments)

Sierra Oncology reports net loss $0.19 per share
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Sierra Oncology Inc ::Sierra Oncology reports third quarter results.Qtrly ‍net loss per share, basic and diluted $0.19​.  Full Article

ProNAi licenses oncology drug targeting DNA damage response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund, UK
Tuesday, 27 Sep 2016 

ProNAi Therapeutics Inc : ProNAi will pay CRT Pioneer fund an upfront payment of us$7.0 million . Additional payments in aggregate amount of up to $319.5 million may become payable upon achievement of certain development,among others . ProNAi licenses oncology drug targeting DNA damage response Checkpoint kinase 1 (Chk1) from CRT Pioneer Fund, UK . PNT737 currently in phase 1 clinical trials at Royal Marsden, London, UK .Has obtained an exclusive license from CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737.  Full Article

ProNAi Therapeutics Q2 net loss of $12.9 mln
Friday, 12 Aug 2016 

ProNAi Therapeutics Inc : ProNAi Therapeutics reports second quarter 2016 results .Qtrly net loss of $12.9 million compared to a net loss of $15.2 million.  Full Article

Pronai licenses cancer drug candidate from Carna Biosciences
Friday, 27 May 2016 

Pronai Therapeutics Inc : Pronai licenses cancer drug candidate targeting CDC7 from Carna Biosciences . Qtrly has obtained an exclusive license from Carna Biosciences, Inc., Kobe, Japan . License for worldwide rights to develop and commercialize as-141, a small molecule kinase inhibitor targeting CDC7 .Will intially pay Carna $0.9 million and additional potential payments upon achievement of certain milestones of upto $270 million.  Full Article

ProNAi Therapeutics qtrly net loss per share $0.35
Tuesday, 10 May 2016 

Pronai Therapeutics Inc : Qtrly net loss per share $0.35 . Q1 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S .Pronai therapeutics reports first quarter 2016 results.  Full Article

ProNAi Therapeutics Inc says FDA granted orphan drug designation for PNT2258
Monday, 14 Mar 2016 

ProNAi Therapeutics Inc:Says oncology drug candidate PNT2258 has been granted orphan drug designation by U.S. Food and Drug Administration for treatment of diffuse large B-cell lymphoma.  Full Article

BRIEF-Sierra Oncology reports net loss $0.19 per share

* Qtrly ‍net loss per share, basic and diluted $0.19​ Source text for Eikon: Further company coverage: